Hospira Gemcitabine Injection (38 mg/mL) 200 mg/5.26 mL (US) Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine injection (38 mg/ml) 200 mg/5.26 ml (us)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml; water for injections - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid - ovarian cancer, breast cancer, non small cell lung cancer, pancreatic cancer

Hospira Gemcitabine Injection 38 mg/mL, 2 g/52.6 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine injection 38 mg/ml, 2 g/52.6 ml vial

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Hospira Gemcitabine Injection 38 mg/mL, 1 g/26.3 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine injection 38 mg/ml, 1 g/26.3 ml vial

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Hospira Gemcitabine Injection 38 mg/mL, 200 mg/5.3 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine injection 38 mg/ml, 200 mg/5.3 ml vial

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - gemcitabine is indicated for treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc). gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelian ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy. gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Gemcitabine IV Infusion 1 g/ 26.3 mL Hospira Australia - English - Department of Health (Therapeutic Goods Administration)

gemcitabine iv infusion 1 g/ 26.3 ml hospira

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - non-small cell lung cancer, pancreatic cancer, biliary tract cancer, uroepithelial cancer, inoperable or recurrent breast cancer, ovarian cancer progressing after chemotherapy, recurrence or refractory malignant lymphoma

Gemcitabine IV Infusion 200 mg/ 5.3 mL Hospira Australia - English - Department of Health (Therapeutic Goods Administration)

gemcitabine iv infusion 200 mg/ 5.3 ml hospira

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide

Hospira Gemcitabine Injection (38 mg/mL) 1 g/26.3 mL (US) Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine injection (38 mg/ml) 1 g/26.3 ml (us)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - ovarian cancer, breast cancer, non small cell lung cancer, pancreatic cancer

Hospira Gemcitabine Injection (38 mg/mL) 2 g/52.6 mL (US) Australia - English - Department of Health (Therapeutic Goods Administration)

hospira gemcitabine injection (38 mg/ml) 2 g/52.6 ml (us)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 43.27 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - ovarian cancer, breast cancer, non small cell lung cancer, pancreatic cancer

Gemcitabine Kabi gemcitabine (as hydrochloride) 2000 mg/52.6 mL concentrated solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

gemcitabine kabi gemcitabine (as hydrochloride) 2000 mg/52.6 ml concentrated solution for injection vial

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 2277.2 mg (equivalent: gemcitabine, qty 2000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Gemcitabine Kabi gemcitabine (as hydrochloride) 1000 mg/26.3 mL concentrated solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

gemcitabine kabi gemcitabine (as hydrochloride) 1000 mg/26.3 ml concentrated solution for injection vial

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 1138.6 mg (equivalent: gemcitabine, qty 1000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.